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background:  Activation of the sympathetic nervous system through substance P has been reported when there is DPP-4 inhibition (DPP-
4i) in the presence of high dose ACE inhibition (ACEi). This has led to concerns of potential increases in CV events when the 2 classes of 
drugs are used together; hence, we evaluated CV outcomes from the large CV outcomes trial EXAMINE according to ACEi use.
Methods:  Patients with T2DM with a recent ACS were randomly assigned to receive alogliptin or placebo added to existing anti-
hyperglycemic and CV prophylactic therapies. Major CV events were adjudicated by a committee blinded to treatment assignment. Risks of 
CV death, nonfatal MI and stroke, and hospitalized HF (HHF) were analyzed using a Cox proportional hazards model in patients with and 
without baseline ACEi.
Results:  There were 5380 patients randomized for a median follow-up of 18 months. At baseline, 3323 (62%) of EXAMINE patients were 
using an ACE inhibitor (1681 on alogliptin; 1642 on placebo) The composite rates of CV mortality, nonfatal MI and stroke were similar 
for alogliptin vs placebo with ACEi [11.4% vs 11.8%, HR = 0.97, 95% CI, 0.79-1.19, p=0.76] and without ACEi use at baseline [11.2% 
vs 11.9%, HR = 0.94, 95% CI, 0.73-1.21, p = 0.62]. CV death or HHF in patients on ACEi use at baseline occurred in 6.8% patients on 
alogliptin vs. 7.2% on placebo [HR=0.93, 95% CI, 0.72-1.2, p = 0.57]. In addition, alogliptin showed no effect on HHF alone in ACEi treated 
patients, 3.3% vs. 3.1%, HR = 1.07, 95% CI, 0.73-1.56, p = 0.75) for alogliptin vs. placebo, respectively. There were also no significant 
differences for these endpoints in patients without ACEi use at baseline. Subgroup analyses according to any pre-randomization history 
of HF and ACEi use at baseline showed the primary endpoint (CV death, MI, and stroke) occurring in 13.9% and 16.5% of patients on 
alogliptin vs placebo, respectively [HR = 0.87, 95% CI, 0.63-1.19, p = 0.38] and CV death or HHF in 12% and 13.2% of patients on 
alogliptin vs placebo, respectively [HR = 1.02, 95% CI, 0.72-1.44, p = 0.92].
conclusion:  Cardiovascular outcomes were not different for alogliptin compared with placebo in patients with T2DM and coronary disease 
treated with ACE inhibitors.
